| 1 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2693).
|
| 2 |
Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
|
| 3 |
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
|
| 4 |
BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
|
| 5 |
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
|
| 6 |
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
|
| 7 |
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
|
| 8 |
Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
|
| 9 |
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
|
| 10 |
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
|
| 11 |
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
|
| 12 |
Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
|
| 13 |
Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
|
| 14 |
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
|
| 15 |
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
|
| 16 |
Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
|
| 17 |
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
|
| 18 |
Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
|
| 19 |
Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
|
| 20 |
Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
|
| 21 |
Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
|
| 22 |
The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
|
| 23 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
|
| 24 |
Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
|
| 25 |
Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
|
| 26 |
Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
|
| 27 |
UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
|
| 28 |
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
|
| 29 |
Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
|
| 30 |
Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
|
| 31 |
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
|
| 32 |
Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
|
| 33 |
Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
|
| 34 |
Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
|
| 35 |
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
|
| 36 |
Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
|
| 37 |
Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
|
| 38 |
The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
|
| 39 |
Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
|
| 40 |
A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
|
| 41 |
Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
|
| 42 |
Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
|
| 43 |
Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
|
| 44 |
Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
|
| 45 |
Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
|
| 46 |
Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
|
| 47 |
Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
|
| 48 |
Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
|
| 49 |
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
|
| 50 |
PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
|
| 51 |
Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
|
| 52 |
Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
|
| 53 |
Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
|
| 54 |
Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
|
| 55 |
Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
|
| 56 |
Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
|
| 57 |
New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
|
| 58 |
A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
|
| 59 |
A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
|
| 60 |
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
|
| 61 |
Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
|
| 62 |
CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
|
| 63 |
Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
|
| 64 |
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
|
| 65 |
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
|
| 66 |
Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
|
| 67 |
Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
|
| 68 |
Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
|
| 69 |
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
|
| 70 |
Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
|
| 71 |
Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
|
| 72 |
UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
|
| 73 |
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
|
| 74 |
Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
|
| 75 |
S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
|
| 76 |
Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
|
| 77 |
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
|
| 78 |
The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
|
| 79 |
UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
|
| 80 |
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
|
| 81 |
Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
|
| 82 |
Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
|
| 83 |
Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
|
| 84 |
Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
|
| 85 |
Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
|
| 86 |
Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
|
| 87 |
Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
|
| 88 |
[Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
|
| 89 |
Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
|
| 90 |
In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
|
| 91 |
UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
|
| 92 |
Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
|
| 93 |
Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
|
| 94 |
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
|
| 95 |
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
|
| 96 |
A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
|
| 97 |
Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
|
| 98 |
Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
|
| 99 |
Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
|
| 100 |
Cerner Multum, Inc. "Australian Product Information.".
|
| 101 |
Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
|
| 102 |
Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
|
| 103 |
Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
|
| 104 |
Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
|
| 105 |
Burgess SJ, Singer GG, Brennan DC "Effect of troglitazone on cyclosporine whole blood levels." Transplantation 66 (1998): 272. [PMID: 9701278]
|
| 106 |
Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
|
| 107 |
Cerner Multum, Inc. "UK Summary of Product Characteristics.".
|
| 108 |
Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
|
| 109 |
Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
|
| 110 |
Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
|
| 111 |
Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
|
| 112 |
Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
|
| 113 |
Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
|
| 114 |
Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
|
| 115 |
Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
|
| 116 |
Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
|
| 117 |
Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
|
| 118 |
Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
|
| 119 |
Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 120 |
Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
|
| 121 |
Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
|
| 122 |
Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
|
| 123 |
Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
|
| 124 |
Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
|
| 125 |
Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
|
| 126 |
Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
|
| 127 |
Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
|
| 128 |
Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
|
| 129 |
FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 31 (2005): 139-51. [PMID: 15921558]
|
| 130 |
Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ "Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent." J Clin Pharmacol 39 (1999): 410-7. [PMID: 10197300]
|
| 131 |
Heinonen J, Takki S, Jarho L "Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes." Acta Anaesthesiol Scand 14 (1970): 89-95. [PMID: 5428253]
|
| 132 |
Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
|
| 133 |
Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
|
| 134 |
He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
|
| 135 |
Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
|
| 136 |
Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
|
| 137 |
Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
|
| 138 |
Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
|
| 139 |
Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
|
| 140 |
Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
|
| 141 |
Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
|
| 142 |
Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
|
| 143 |
Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
|
| 144 |
Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
|
| 145 |
Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
|
| 146 |
Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
|
| 147 |
Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
|
| 148 |
Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
|
| 149 |
Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
|
| 150 |
Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 151 |
Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
|
| 152 |
Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
|
| 153 |
Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
|
| 154 |
Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
|
| 155 |
Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
|
| 156 |
Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
|
| 157 |
Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
|
| 158 |
Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
|
| 159 |
Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
|
| 160 |
Canadian Pharmacists Association.
|
| 161 |
Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
|
| 162 |
Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
|
| 163 |
Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
|
| 164 |
Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
|
| 165 |
Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48. [PMID: 11298070]
|
| 166 |
Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
|
| 167 |
Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
|
| 168 |
Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
|
| 169 |
Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
|
| 170 |
Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
|
| 171 |
Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
|
| 172 |
Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
|
| 173 |
Cerner Multum, Inc. "Canadian Product Information.".
|
| 174 |
Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
|
| 175 |
Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
|
| 176 |
Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
|
| 177 |
Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
|
| 178 |
Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 179 |
Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
|
| 180 |
Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
|
| 181 |
Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
|
| 182 |
Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
|
| 183 |
Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
|
| 184 |
Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
|
| 185 |
Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
|
| 186 |
Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
|
| 187 |
Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
|
| 188 |
Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
|
| 189 |
Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
|
| 190 |
Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
|
| 191 |
Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 192 |
Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
|
| 193 |
Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 194 |
Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
|
| 195 |
Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 196 |
Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
|
| 197 |
Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
|
| 198 |
Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
|
| 199 |
Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
|
| 200 |
EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
|
| 201 |
Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
|
| 202 |
Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
|
| 203 |
Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
|
| 204 |
Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
|
| 205 |
Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
|
| 206 |
Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
|
| 207 |
Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
|
| 208 |
Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
|
| 209 |
Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
|
| 210 |
Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
|
| 211 |
Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
|
| 212 |
Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
|
| 213 |
Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
|
| 214 |
Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
|
| 215 |
Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A "The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s65-70. [PMID: 10771457]
|
| 216 |
Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
|
| 217 |
Fraser CG, Fierro L "Comment: troglitazone." Ann Pharmacother 32 (1998): 1111-2. [PMID: 9793612]
|
| 218 |
Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
|
| 219 |
Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
|
| 220 |
DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
|
| 221 |
Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
|
| 222 |
Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
|
| 223 |
Plowman BK, Morreale AP "Possible troglitazone-warfarin interaction." Am J Health Syst Pharm 55 (1998): 1071. [PMID: 9606460]
|
| 224 |
Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
|
| 225 |
Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
|
| 226 |
Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
|
| 227 |
Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
|
| 228 |
Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
|
|
|
|
|
|
|
